M
Maxime Dougados
Researcher at University of Paris
Publications - 1144
Citations - 78022
Maxime Dougados is an academic researcher from University of Paris. The author has contributed to research in topics: Rheumatoid arthritis & Ankylosing spondylitis. The author has an hindex of 134, co-authored 1054 publications receiving 69979 citations. Previous affiliations of Maxime Dougados include French Institute of Health and Medical Research & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
Martin Rudwaleit,D. van der Heijde,Robert Landewé,Joachim Listing,Nurullah Akkoc,J Brandt,Jürgen Braun,C.T. Chou,Eduardo Collantes-Estevez,Maxime Dougados,Feng Huang,Jieruo Gu,Muhammad Asim Khan,Yesim Kirazli,Walter P. Maksymowych,Herman Mielants,Inge Juul Sørensen,Salih Ozgocmen,Euthalia Roussou,R. Valle-Oñate,Ulrich Weber,James Cheng-Chung Wei,Joachim Sieper +22 more
TL;DR: The new ASAS classification criteria for axial SpA can reliably classify patients for clinical studies and may help rheumatologists in clinical practice in diagnosing axial spondyloarthritis in those with chronic back pain.
Journal ArticleDOI
The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy
Maxime Dougados,van der Linden S,Juhlin R,Huitfeldt B,Bernard Amor,Andrei Calin,A. Cats,Ben A. C. Dijkmans,Ignazio Olivieri,Pasero G +9 more
TL;DR: The proposed classification criteria for spondylarthropathy are easy to apply in clinical practice and performed well in all 7 participating centers and are regarded as preliminary until they have been further evaluated in other settings.
Journal ArticleDOI
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley Cohen,Paul Emery,Maria Greenwald,Maxime Dougados,Richard Furie,Mark C. Genovese,Edward C. Keystone,J.E. Loveless,Gerd-Rüdiger Burmester,M. Cravets,E. W. Hessey,T. Shaw,Mark C. Totoritis +12 more
TL;DR: At 24 weeks, a single course of rituximab with concomitant MTX therapy provided significant and clinically meaningful improvements in disease activity in patients with active, longstanding RA who had an inadequate response to 1 or more anti-TNF therapies.
Journal ArticleDOI
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
Martin Rudwaleit,D. van der Heijde,Robert Landewé,Nurullah Akkoc,J Brandt,C.T. Chou,Maxime Dougados,Feng Huang,Jieruo Gu,Yesim Kirazli,F. Van den Bosch,Ivana Olivieri,Euthalia Roussou,Salvatore Scarpato,Inge Juul Sørensen,R. Valle-Oñate,Ulrich Weber,James Cheng-Chung Wei,J. Sieper +18 more
TL;DR: The new ASAS classification criteria for peripheral SpA performed well in patients presenting with peripheral arthritis, enthesitis and/or dactylitis, particularly regarding sensitivity.
Journal ArticleDOI
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
Joachim Sieper,M. Rudwaleit,Xenofon Baraliakos,J Brandt,Jürgen Braun,Ruben Burgos-Vargas,Maxime Dougados,K.-G. Hermann,Robert Landewé,Walter P. Maksymowych,D. van der Heijde +10 more
TL;DR: A comprehensive handbook on the most relevant aspects for the assessments of spondyloarthritis, covering classification criteria, MRI and x rays for sacroiliac joints and the spine, a complete set of all measurements relevant for clinical trials and international recommendations for the management of SpA are provided.